Assessing Omega-3 Therapy and Its Cardiovascular Benefits: What About Icosapent Ethyl? A Systematic Review and Meta-Analysis DOI Creative Commons

Nathália Mendes Machado,

Maria Júlia Ribeiro de Oliveira, Karina Quesada

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(4), P. 601 - 601

Published: April 20, 2025

Background: Lipid-lowering therapies are an option for stabilizing lipid levels. Icosapent ethyl (IPE) is a highly purified formulation of eicosapentaenoic acid, which can reduce action, improve plaque stabilization, platelet aggregation, lower TG, and prevent cardiovascular events. IPE frequently used with statins to manage elevated TG However, the evidence on as lipid-lowering agent limited, no updated systematic review meta-analysis have been published considering recent advancements in field newly studies. Therefore, we aim fill this gap. Methods: We PRISMA guidelines PICO (Population, Intervention, Comparison, Outcome) framework conduct review, aiming answer question, “Can benefit patients at risk?” GRADE was evaluate levels adhere highest criteria. Results: Predominantly, evaluated population presented between ≥135 mg/dL 500 LDL-C >40 ≤100 mg/dL. The included studies showed reduction decrease It means that, according our analysis, has effective lowering blood levels, including reducing death events, such non-fatal stroke or hospitalization unstable angina. it worth noting that these results were primarily from undergoing statin therapy. According meta-analysis, may not be considered drug, limited action associated its use evident quantitative results. caution necessary, only two suitable inclusion due differing outcomes analyzed samples. Conclusions: Despite synthesis, possesses anti-inflammatory, anti-thrombotic, anti-atherogenic properties, related protection. Based studies, promising therapy atherosclerotic disease conjunction other therapies, particularly statins, extremely high limitations reviewed include small sample sizes, varying outcomes, duration interventions. Future clinical trials similar intervention durations must designed, meta-analyses following years fully assess effects protector drug.

Language: Английский

Assessing Omega-3 Therapy and Its Cardiovascular Benefits: What About Icosapent Ethyl? A Systematic Review and Meta-Analysis DOI Creative Commons

Nathália Mendes Machado,

Maria Júlia Ribeiro de Oliveira, Karina Quesada

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(4), P. 601 - 601

Published: April 20, 2025

Background: Lipid-lowering therapies are an option for stabilizing lipid levels. Icosapent ethyl (IPE) is a highly purified formulation of eicosapentaenoic acid, which can reduce action, improve plaque stabilization, platelet aggregation, lower TG, and prevent cardiovascular events. IPE frequently used with statins to manage elevated TG However, the evidence on as lipid-lowering agent limited, no updated systematic review meta-analysis have been published considering recent advancements in field newly studies. Therefore, we aim fill this gap. Methods: We PRISMA guidelines PICO (Population, Intervention, Comparison, Outcome) framework conduct review, aiming answer question, “Can benefit patients at risk?” GRADE was evaluate levels adhere highest criteria. Results: Predominantly, evaluated population presented between ≥135 mg/dL 500 LDL-C >40 ≤100 mg/dL. The included studies showed reduction decrease It means that, according our analysis, has effective lowering blood levels, including reducing death events, such non-fatal stroke or hospitalization unstable angina. it worth noting that these results were primarily from undergoing statin therapy. According meta-analysis, may not be considered drug, limited action associated its use evident quantitative results. caution necessary, only two suitable inclusion due differing outcomes analyzed samples. Conclusions: Despite synthesis, possesses anti-inflammatory, anti-thrombotic, anti-atherogenic properties, related protection. Based studies, promising therapy atherosclerotic disease conjunction other therapies, particularly statins, extremely high limitations reviewed include small sample sizes, varying outcomes, duration interventions. Future clinical trials similar intervention durations must designed, meta-analyses following years fully assess effects protector drug.

Language: Английский

Citations

0